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Abstract
Background: DNA CpG methylation is carried out by DNA methyltransferases and induces chromatin remodeling
and gene silencing through a transcription repressor complex comprising the methyl-CpG-binding protein 2
(MeCP2) and a subset of histone deacetylases. Recently, we have found that MeCP2 activity had a crucial role in
the pattern of gene expression seen in the superficial dorsal horn rapidly after injection of Complete Freund’s
Adjuvant (CFA) in the rat ankle joint. The aim of the present study was to analyse the changes in expression of
MeCP2, DNA methyltransferases and a subset of histone deacetylases in the superficial dorsal horn during the
maintenance phase of persistent pain states. In this process, the cell specific expression of MeCP2 was also
investigated.
Results: Using immunohistochemistry, we found that neurones, oligodendrocytes and astrocytes expressed MeCP2.
Microglia, oligodendrocyte precursor cells and Schwann cells never showed any positive stain for MeCP2.
Quantitative analyses showed that MeCP2 expression was increased in the superficial dorsal horn 7 days following
CFA injection in the ankle joint but decreased 7 days following spared nerve injury. Overall, the expression of DNA
methyltransferases and a subset of histone deacetylases followed the same pattern of expression. However, there
were no significant changes in the expression of the MeCP2 targets that we had previously shown are regulated in
the early time points following CFA injection in the ankle joint. Finally, the expression of MeCP2 was also down
regulated in damaged dorsal root ganglion neurones following spared nerve injury.
Conclusion: Our results strongly suggest that changes in chromatin compaction, regulated by the binding of
MeCP2 complexes to methylated DNA, are involved in the modulation of gene expression in the superficial dorsal
horn and dorsal root ganglia during the maintenance of persistent pain states.
Keywords: MeCP2, Astrocyte, Microglia, Spinal nerve injury, Inflammation, Chronic pain, DNA methyltransferase,
Histone deacetylase
Background
The induction and maintenance of persistent pain states,
whether inflammatory or neuropathic, involve a number
of changes in gene expression both in the dorsal root
ganglia (DRGs) [1-4] and in the spinal cord [5-7]. Regula-
tion of gene expression can be achieved through DNA
CpG methylation, a process implemented by DNA methyl-
transferases (DNMTs). DNA methylation induces chroma-
tin remodeling and gene silencing through a
transcriptional repressor complex comprising the Methyl-
CpG-binding protein 2 (MeCP2) and a subset of histone
deacetylases (HDACs) [8]. Recently, we have found that
MeCP2 activity had a crucial role in the pattern of gene
expression seen in the superficial dorsal horn following
injection of Complete Freund’s Adjuvant (CFA) into the
rat ankle joint [5]. A rapid increase in expression of a
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MeCP2 occurred following CFA injection. These included
the serum- and glucocorticoid- regulated kinase (SGK1),
FK 506 binding protein 5 (FKBP5), a glucocorticoid recep-
tor-regulating co-chaperone of hsp-90, and the sulfotrans-
ferase family 1A, phenol-preferring, member 1
(SULT1A1). Crucially, we found that SGK1 supported the
induction of ankle joint inflammation indicating a key role
for MeCP2 controlled epigenetic mechanisms in the
induction of persistent pain states [5].
Patterns of DNA methylation are established and
maintained by DNMTs. Although this process has gen-
erally been regarded as a fairly stable event in the adult
animal, recent evidence suggests that it is dynamically
regulated in the adult nervous system and that this may
be crucial for synaptic plasticity and memory formation
[9]. Since pain processing and memory formation share
a number of mechanisms and are both dependent on
synaptic plasticity, it is likely that DNA methylation and
therefore DNMT activity is regulated during the devel-
opment of long-term pain states. HDAC expression is
s i m i l a r l yl i k e l yt oc h a n g ei nl o n g - t e r mp a i ns t a t e s .
Indeed, HDACs contribute to chromatin compaction by
removing acetyl groups on histone tails allowing for
interaction with the DNA backbone. Others have shown
that a subset of HDACs were regulated during the
short-term thermal hyperalgesia that develops after
injection of CFA into the hindpaw [10]. Here, we
focused our interest on specific HDAC isoforms, namely
HDAC 1 and 2, known to be part of the MeCP2 repres-
sor complex [8] and HDAC 5, the isoform exhibiting
the greatest change in the spinal cord after injection of
CFA in the hindpaw [10].
In the present study, we analysed the expression levels
of MeCP2, DNMTs and HDACs in two models of per-
sistent pain states (ankle joint inflammation induced by
CFA [5] and spared nerve injury, SNI [11,12]). Changes
in mRNA expression were analysed 7 days after the
initial insult, a time point when mechanical hyperalgesia
is stable. We additionally investigated the cell specificity
of MeCP2 expression in the superficial dorsal horn. The
role of MeCP2 in the induction of pain states has so far
been investigated in neurones [5,13], but recent studies
have shown that MeCP2 was expressed in subsets of
glial cells [14-18]. Considering the key role of glia in the
development of chronic pain states [19,20], specifically
astrocytes [21-23] and microglia [24-26], the potential
role for glial MeCP2 needs to be examined.
Results
Cell specific expression of MeCP2 in the superficial dorsal
horn
The neuronal and glial expression of MeCP2 was inves-
tigated in the superficial dorsal horn of animals that had
undergone SNI surgery 7 days before perfusion, animals
that had received a CFA injection in the ankle joint 7
days before perfusion and sham animals for both
groups. While all neurones (anti-neuronal nuclei
(NeuN) positive cells) expressed MeCP2 in all condi-
tions (Figure 1), expression of MeCP2 in glial cells was
at lower levels. Oligodendrocytes (anti-Adenomatosis
Polyposis Coli (APC, CC-1) positive cells; Figure 2A)
and astrocytes (anti-Glial Fibrillary Acidic Protein
(GFAP) positive cells; Figure 2B) expressed MeCP2 only
when saturating the signal from neuronal MeCP2. How-
ever, microglia (anti-Ionized calcium-binding adaptor
molecule 1 (IBa1) positive cells) and oligodendrocyte
precursor cells (OPCs; NG2 positive cells) never showed
any MeCP2 stain (Figure 2C and 2D, respectively).
MeCP2 expression increases in the superficial dorsal horn
7 days post CFA injection in the ankle joint
MeCP2 expression in the superficial dorsal horn was
analysed using RT-qPCR. MeCP2 isoforms e1 and e2
are generated by alternative splicing of exon 2 to pro-
duce proteins with differing N termini [27]. Both
MeCP2 transcripts are expressed almost ubiquitously
with higher expression of the e1 isoform in the brain
[28]. MeCP2 isoforms were investigated using specific
primers [29]. We found a bilateral increase in MeCP2
e1 but a unilateral increase of MeCP2 e2 in the contral-
ateral side 7 days post CFA injection (Figure 3A and
Table 1). We then investigated the expression of the
genes that we had found were under MeCP2 control in
the superficial dorsal horn shortly after CFA injection
into the ankle joint. We found no significant change in
SGK1, FKBP5 and SULT1a1 expression (Figure 3A and
Table 1).
MeCP2 expression decreases in the superficial dorsal horn
7 days post SNI surgery
Both MeCP2 e1 and e2 decreased ipsilaterally following
SNI surgery but again there were no significant changes
in the expression of MeCP2 target genes (Figure 3B and
Table 1).
The expression levels of DNMTs and HDACs in the
superficial dorsal horn parallel that of MeCP2 7 days post
CFA injection in the ankle joint or SNI surgery
Changes in MeCP2 expression in the superficial dorsal
horn are likely to be an indication of changes in chro-
matin compaction. We asked whether the expression
levels of DNMT1, DNMT3a and DNMT3b and that of
a subset of HDACs (HDAC1, 2 and 5) were also modu-
lated during persistent pain states. We found that the
expression pattern of DNMTs and HDACs mirrored
that of MeCP2 with an overall bilateral up-regulation 7
days following injection of CFA in the ankle joint and
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(Figure 3C and 3D respectively, and Table 1).
MeCP2 expression in DRG neurones 7 days post SNI
surgery
Since peripheral nerve damage (SNI) was shown to
reduce MeCP2 expression in the dorsal horn, we wanted
to know what the effect of nerve transection would be
on MeCP2 neuronal levels in DRGs. Our hypothesis was
that MeCP2 would be decreased in injured neurones
allowing for up-regulation of gene expression required
for regeneration. MeCP2 expression was analysed in
DRG sections stained for ATF3, a marker for damaged
neurones, 7 days following SNI surgery (Figure 1, 2, 3).
We measured MeCP2 expression in 4 to 5 DRG sections
per animal, 1 to 9 cells per section in 4 animals. We
found that MeCP2 expression in both small and large
fibers was decreased in ATF3 positive neurones when
compared with ATF3 negative neurones (100 ± 10.1 vs
79.4 ± 8.5 in small fibers, P < 0.05, and 100 ± 8.4 vs
87.6 ± 7.4 in large fibers, P < 0.01; Figure 4A4). Finally,
since MeCP2 was expressed in subsets of glial cells in
the superficial dorsal horn, we analysed MeCP2 expres-
sion in Schwann cells and found that Schwann cells
(S100 positive cells) did not express MeCP2 (Figure 4B).
Discussion
In the present study, we showed that the mRNA levels
of MeCP2, DNMTs and a subset of HDACs were modu-
lated in the superficial dorsal horn during persistent
pain states, suggesting that the state of chromatin com-
paction is regulated during the maintenance phase of
chronic pain states. We also looked at the cell specificity
of MeCP2 expression and found that MeCP2 was
expressed in neurones and in non-neuronal cells,
specifically astrocytes and oligodendrocytes, but at much
lower levels. However the changes in MeCP2 expression
were measured by RT-qPCR and therefore not attributa-
ble to a specific cell type.
Cell specific expression of MeCP2
The cell specificity of MeCP2 expression is a source of
controversy [30]. While a number of studies have found
that MeCP2 was not expressed in glial cells [28,31-34],
more recent studies clearly showed MeCP2 expression
in astrocytes, OPCs, oligodendrocytes [14,15,18,35] and
microglia [14,16]. Authors of these studies suggested
that the discrepancies with previous reports were due to
the use of different primary antibodies and different
immunohistochemical methodologies. Clearly the choice
of the antibody is of crucial importance and we have
found that some anti-MeCP2 antibodies can indeed lead
to false positive staining (see Methods section). In the
present study, we have stained rat spinal cord tissue
with a commercial antibody (Millipore) successfully
used by others to show MeCP2 expression in glial cells
i nm o u s eb r a i nt i s s u e[ 1 5 , 1 6 ] .W eh a v ea l s oa p p l i e da
TSA amplification method which can reveal the expres-
sion of a protein at a very low level. Under these condi-
tions, we found that MeCP2 was expressed in astrocytes
and oligodendrocytes but at much lower levels than in
neurones. However, we failed to confirm the expression
of MeCP2 by OPCs and microglia. Considering that
others have clearly shown that the level of MeCP2 in
microglia in the brain is even lower than that in astro-
cytes [16], it could be that the level of expression of
MeCP2 in microglia in the spinal cord is not detectable
in the present conditions. MeCP2 expression levels have
indeed been reported to show important regional varia-
tion [34] and therefore this could also explain why we
MeCP2
+
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Figure 1 All neurones express MeCP2 in the rat superficial dorsal horn.C o n f o c a li m a g e so fr a ts u p e r f i c i a ld o r s a lh o r ns e c t i o n s .
Colocalization of MeCP2 (green; Millipore antibody) and NeuN (red). MeCP2 can be seen within the nucleus of all neurones (arrows). However,
some MeCP2 staining is clearly non-neuronal (arrow heads). Pictures show single focal plane. Scale bars, 1) 50 μm and 2) 20 μm.
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cytes while others have reported a similar level of
expression for MeCP2 in both cell types in the brain
[14].
Changes in MeCP2, DNMT and HDAC expression during
the maintenance phase of persistent pain states
Regardless of the cell type, while we did not observe any
significant changes in MeCP2 phosphorylation in the
spinal cord 7 days following injection of CFA in the
ankle joint or SNI surgery (data not shown), we found
some significant changes in the level of expression of
MeCP2. While MeCP2 was up-regulated in the model
of inflammation, there was a clear downregulation in
the neuropathic model. These changes were paralleled
by that of DNMTs and a subset of HDACs. Patterns of
DNA methylation are established and maintained by
DNMTs. While DNMT1 is the maintenance DNMT
that ensures that methylation patterns are copied faith-
fully throughout each cell division, DNMT3a and
Figure 2 MeCP2 is expressed in oligodendrocytes and astrocytes, but not in microglia or oligodendrocyte precursor cells, in the rat
superficial dorsal horn. Confocal images of rat superficial dorsal horn sections. A, Colocalization of MeCP2 (green; Millipore antibody) and APC
(red). MeCP2 can be seen within the nucleus of oligodendrocytes. B, Colocalization of MeCP2 (green; Millipore antibody), GFAP (red) and DAPI, a
nuclear marker (blue). MeCP2 can be seen within the nucleus of astrocytes. C, Expression of MeCP2 (green; Millipore antibody) and IBA1 (red).
MeCP2 stain cannot be seen within microglia. D, Expression of MeCP2 (green; Millipore antibody), NG2 (red) and DAPI, a nuclear marker (blue).
MeCP2 stain cannot be seen within OPCs. Pictures show single focal plane. Scale bars, 1) 50 μm and 2) 20 μm.
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response to environmental factors. An up-regulation of
DNMT expression together with an up-regulation of
MeCP2 and a subset of HDACs would suggest an
increase in chromatin compaction and therefore an
overall downregulation of gene expression. Indeed, we
found in a previous microarray study that there was a
majority of down regulated genes in the superficial dor-
sal horn 7 days following CFA injection in the ankle
joint. Remarkably, we have also shown that 2-6 h after
CFA injection in the ankle joint gene transcription is
globally upregulated while the expression of MeCP2,
DNMTs and the same subsets of HDACs is decreased
[5,36].
The downregulation of MeCP2, DNMTs and HDACs
7 days following SNI should also indicate an overall up-
regulation of gene expression in the maintenance phase
of this persistent pain model. A number of microarray
studies have looked at changes at gene expression in
neuropathic pain models but many have focused on
DRGs and only few have investigated the superficial
dorsal horn and classified both up and down regulated
genes [7,37]. However, it was shown that there are a
majority of up-regulated genes 7 days following L5
transection which would support our present finding [7].
Remarkably the changes in epigenetic mediators in the
superficial dorsal horn were bilateral in our model of
joint inflammation. This was not surprising since many
studies report contralateral effects in arthritis models.
Although poorly understood, neurogenic mechanisms
are believed to be central to the development and main-
tenance of these contralateral effects [38]. Specifically, in
the model of CFA induced joint inflammation, symme-
try of joint involvement is seen after 2 to 4 weeks
[39,40] while contralateral sensory nerves show altered
function prior to evident signs of inflammation [41].
These observations could explain the bilateral changes
in epigenetic mediators seen in the present study.
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Figure 3 Expression of MeCP2, DNMTs and HDACs increases within the dorsal horn 7 days following CFA injection in the ankle joint
but decreases 7 days following SNI surgery. The expression of MeCP2, downstream targets, DNMTs and HDACs was quantified by RT-qPCR. Y
axis represents mRNA expression as a percentage of control (sham animals). Data show mean ± SEM. *: P < 0.05 and ** P < 0.01 sham vs contra;
# P < 0.05, ## P < 0.01 and ###: P < 0.001 sham vs ipsi; $ P < 0.05 ipsi vs contra. CFA: N = 5 in each group and SNI: N = 7 in each group.
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cate that MeCP2 is likely to be involved in the regula-
tion of genes responsible for sustaining an increased
level of hypersensitivity during the maintenance of per-
sistent pain states. However, 7 days post CFA injection
or post-SNI, there were no significant changes in the
expression of the MeCP2 targets that were modulated
during the onset of CFA induced ankle inflammation
[5]. These results suggest that, even when the mechani-
cal hyperalgesia has reached a steady level, the combina-
tion of genes expressed during the course of a persistent
pain state is highly specific to the pain model and time
point studied.
Finally, this study is the first to look at MeCP2 expres-
sion within DRGs. We found that MeCP2 levels were
decreased in ATF3 positive neurones after SNI. MeCP2
therefore probably contributes to the large changes in
gene expression seen in DRGs after SNI surgery as well
as other neuropathic pain models [1,3,42] by permitting
the expression of regeneration associated genes.
DNMT inhibitors, HDAC inhibitors and the regulation of
inflammatory pain states
Our results show that DNMT and HDAC mRNAs are up-
regulated within the superficial dorsal horn 7 days follow-
ing CFA injection in the ankle joint. This raises the possi-
bility that DNMT and HDAC inhibitors might reduce the
long-term increase in sensitivity induced by CFA. A pre-
vious study showed that the intrathecal injection of zebu-
larine, a DNA methylation inhibitor that forms a covalent
complex with DNA methyltransferases, reduced pain sen-
sitivity when administered shortly before or after CFA
injection in the hindpaw [43]. However the alleviation of
the hypersensitivity was short lived (1 h) and zebularine
was inefficient at reducing pain sensitivity when given 24
h after CFA. HDAC inhibitors have also been shown to
provide analgesia in models of hindpaw inflammation
[10,44] but whether these effects could be long-term is
again unknown. The possibility that DNMT and HDAC
inhibitors could reduce the sensitivity induced by CFA
injection in the ankle joint also remain to be explored.
Table 1 Primers sequence for RT-qPCR and results of RT-qPCR analysis.
mRNA Primers sequence CFA SNI
Ispi
vs Sham
Contra
vs Sham
Ispi
vs Sham
Contra
vs Sham
MeCP2 e1 F 5’-ggagagactggaggaaaagtca-3’ 137% ** 158% * 74% * ns
R5 ’-ccttcttaaacttcaggggtttc-3’
MeCP2 e2 F 5’-ctgtttgggagaagcagagg-3’ ns 134% * 85% * ns
R5 ’-tggtagctgggatgttaggg-3’
FKBP5 F 5’-caccctgagcctggagagag-3’ ns ns ns ns
R5 ’-gtgtcgccattactcgcagag-3’
SGK1 F 5’-gggctgtcttgtatgagatgc-3’ ns ns ns ns
R5 ’-gtgccttgctgagttggtg-3’
SULT1a1 F 5’-ccgaggagactgtggattc-3’ ns ns ns ns
R5 ’-gcatagtgggcatcaaagc-3’
DNMT1 F 5’-ggagtgtgtgaaagagaaa-3’ 112% * 114% ** 87% * ns
R5 ’-tagccttcctcagacaat-3’
DNMT3a F 5’-aattgtgtcttggtggat-3’ 125% * 124% * ns ns
R5 ’-actgagaatttgccatct-3’
DNMT3b F 5’-ggagacagcagacatctt-3’ ns 131% * ns ns
R5 ’-gtcactacagttcccattaac-3’
HDAC1 F 5’-cctcaccgaatccgaatg-3’ 120% * 128% ** ns ns
R5 ’-cgaatagaacgcaagaacttg-3’
HDAC2 F 5’-tcaagtttctacgatcaataagg-3’ ns ns ns 90% *
R5 ’-cttctccgacattaaatctctg-3’
HDAC5 F 5’-aagtacgttcaaggctaa-3’ 117% ** 114% ** 77% *** ns
R5 ’-cgactgctctcttcttaa-3’
b-Actin F 5’-agattactgccctggctccta-3’ ns ns ns ns
R5 ’-aggatagagccaccaatccac-3’
HGPRT F 5’-aggacctctcgaagtgttggatac-3’ ns ns ns ns
R5 ’-tgtagattcaacttgccgctgtc-3’
* P < 0.05; ** P < 0.01; ns: non significant. CFA N = 5 in each group and SNI N = 7 in each group
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While our data show changes in MeCP2 expression in
the superficial dorsal horn, we did not determine in
which cell type these changes occurred. Since the
expression level of MeCP2 is much greater in neurones
than in glia, we could expect the MeCP2 changes to
reflect neuronal expression levels. This would be sup-
ported by our previous study that showed changes in
MeCP2 phosphorylation specifically in neurones of the
superficial dorsal horn 1 h after CFA injection in the
ankle joint. However, these changes in MeCP2 expres-
sion levels could also be due to large changes in
astrocytic MeCP2 levels. Although it was recently
reported that changes in DNA methylation do not seem
to occur within microglia and astrocytes [45], glial
MeCP2 seem to be crucial to normal CNS functions.
Rett syndrome (RTT) is an X-chromosome linked aut-
ism spectrum disorder caused by mutations in the gene
encoding MeCP2. Until recently the disease was attribu-
ted to the loss of MeCP2 function in neurons [30].
However, new studies have challenged this assumption
by showing that MeCP2 deficient glia causes abnormal-
ities in neighbouring neurones, strongly suggesting that
glia has a role in the progression of Rett’ss y n d r o m e
MeCP2 expression in DRGs
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Figure 4 MeCP2 expression is reduced within damaged DRG neurons following SNI surgery. A1 to A3, Images of DRG sections 7 days
following SNI surgery. Colocalization of MeCP2 (green; Millipore antibody) and ATF3 (red) in DRG neurones. Arrow indicates neurones expressing
both MeCP2 and ATF3. Scale bar, 20 μm. A4, Measure of MeCP2 expression in ATF3 positive neurons using confocal microscopy. MeCP2
expression was quantified by measuring staining intensity and normalized to MeCP2 expression in ATF3 negative cells within each sub-group
(small and large fibers; cell body diameter < 25 μm and > 25 μm). B, Confocal images of rat dorsal root ganglion sections. Expression of MeCP2
(green; Millipore antibody), S100 (red) and DAPI, a nuclear marker (blue). Pictures show single focal plane. Scale bars, 50 μm.
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development of chronic pain states, the role of spinal
astrocytic MeCP2 in pain states requires further exami-
nation. A crucial experiment would be to find out if
some astrocytic genes are regulated by MeCP2 and con-
tribute to persistent pain states.
Conclusions
Our results clearly show that MeCP2, DNMT and HDAC
levels are modulated within the superficial dorsal horn
during the maintenance phase of persistent pain states. It
is therefore highly likely that changes in DNA methylation
and chromatin compaction contribute to the regulation of
pattern of gene expression responsible for the mainte-
nance of long-term pain states. Finally, since MeCP2 is
not only expressed in neurones but also in subsets of glial
cells, it is crucial to further investigate the role of MeCP2
in glia during chronic pain states, especially in astrocytes.
Methods
Subjects
All procedures complied with the UK Animals (Scienti-
fic Procedures) Act 1986. Male Sprague Dawley rats
(200-220 g; Central Biological Services, University Col-
lege London, UK) were used for all experiments. Ani-
mals were kept in their home cages at 21°C and 55%
relative humidity with a light-dark cycle of 12 h (lights
on at 08:00 h). Food and water were provided ad libi-
tum. All efforts were made to minimise animal suffering
and to reduce the number of animals used.
Antibodies and drugs
We began our study using an antibody against MeCP2
from Sigma. While we only expected a specific nuclear
stain, we observed a clear labelling of astrocytic cyto-
plasm in the rat superficial dorsal horn (Figure 5A). In
order to ascertain the validity of this stain, we used tis-
sue from universal MeCP2 knock-out (KO) animals (gift
from A. Bird) and found out that the antibody we were
using was also labelling astrocytic-like processes in the
dorsal horn of MeCP2 KO mice (Figure 5B1), suggesting
that this was a non-specific stain. In contrast, the anti-
body directed against MeCP2 purchased from Millipore
only showed a specific nuclear stain in wild-type animals
(Figure 5B2 and 5B3). This antibody was therefore used
for the rest of this study.
Anti- MeCP2 was purchased from Sigma (Cat. No:
M6818; C-terminus 741-486) and Millipore (Cat. No:
07-013; C-terminus 465-478). Anti-NG2 was obtained
from Millipore (Cat. No: 05-710); anti-neuronal nuclei
(NeuN) from Chemicon (Cat. No: MAB 377), anti-Glial
Fibrillary Acidic Protein (GFAP) and anti-S100 from
Dako (Cat. No: Z0334 and Z0311, respectively), anti-
Ionized calcium-binding adaptor molecule 1 (IBa1) from
Wako (Cat. No: 019-19741), anti-Adenomatosis Polypo-
sis Coli (APC, CC-1) from Calbiochem (Cat. No: OP
80), anti- 4’,6-diamidino-2-phenylindole (DAPI) from
Invitrogen (Cat. No: D1306) and anti-Activating Tran-
scription Factor 3 (ATF3) from Santa Cruz Biotechnol-
ogy (Cat. No: sc-188). Complete Freund’sA d j u v a n t
(CFA) was purchased from Sigma.
Animal preparation
Ankle joint inflammation
Inflammation was induced by injection of Complete
Freund’s Adjuvant (CFA, Sigma, Poole, UK; 10 μl) in
the left ankle joint, under halothane anaesthesia induced
in a closed chamber delivering 5% halothane combined
GFAP Sigma MeCP2 A
B MeCP2 antibody / Sigma
MeCP2 KO animal
MeCP2 antibody / Millipore
MeCP2 KO animal
1 2 MeCP2 antibody / Millipore
WT animal
3
Figure 5 MeCP2 antibody from Sigma wrongly labels astrocytic processes in the superficial dorsal horn. A, Colocalization of MeCP2
(green; Sigma antibody) and astrocytes (red) in the superficial dorsal horn of naïve rat. B, Images of dorsal horn sections of MeCP2 knock out
animals (gift from A.Bird) stained with anti-MeCP2 antibody from Sigma (1) and from Millipore (2). (3) Dorsal horn of wild type animals (C57BL/6)
stained with the Millipore anti-MeCP2 antibody. Scale bar, 20 μm.
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injection by the delivery (via a face mask) of 1.5-2%
halothane combined with 100% O2 (1 l/min). The needle
entered the ankle joint from the anterior and lateral
positions, with the ankle kept in plantaflexion to open
the joint. Sham treatment consisted of anaesthetizing
the animals only.
Spared nerve injury surgery
The spared nerve injury (SNI) was performed as
described [12]. Under 2% isoflurane anaesthesia the
biceps femoris muscle was exposed and sectioned to
expose the sciatic nerve and its three terminal branches:
the sural, common peroneal and tibial nerves. The com-
mon peroneal and tibial nerves were tightly ligated with
5.0 silk and sectioned distal to the ligation. Care was
taken to avoid touching or stretching the spared sural
nerve. For sham surgery, the sciatic nerve was exposed
as described above but no contact was made with the
nerve.
Immunohistochemistry
For immunohistochemistry, rats were deeply anaesthe-
tized with pentobarbital 7 days after CFA injection, SNI
surgery or relevant sham surgery and perfused transcar-
dially with saline containing 5 000 I.U./ml heparin fol-
lowed by 4% paraformaldehyde (PFA) in 0.1 M
phosphate buffer (PB, 250 ml per adult rat). Lumbar
spinal cord and L4 and L5 dorsal root ganglia (DRGs)
were dissected out, post-fixed in the same PFA solution
for 2 h and transferred into a 30% sucrose solution in
PB containing 0.01% azide at 4°C, for a minimum of 24
h. Spinal cords and DRGs were cut on a freezing micro-
tome set at 40 μm.
Sections were left to incubate with anti-MeCP2 anti-
body for 48 h at 4°C (1: 10 000). Anti-rabbit biotinylated
secondary antibody was used at a concentration of 1:400
and left on for 90 min. Samples were then incubated
with avidin biotin complex (ABC Elite, Vector Lab.;
1:250 Vectastain A + 1:250 Vectastain B) for 30 min fol-
lowed by a signal amplification step with biotinylated
tyramide solution (Perkin Elmer, 1:75 for 7 min). Finally,
sections were incubated with FITC avidin for another 2
h (1:600). For double labelling, sections were left over-
n i g h ta tr o o mt e m p e r a t u r ew i t hs e c o n dp r i m a r ya n t i -
body (anti-NeuN: 1:1000; anti-GFAP: 1:4000; anti-IBa1:
1:2000; anti-S100: 1:1000; anti-NG2: 1:500; anti-APC
(CC-1): 1:200 and anti-ATF3: 1:200). Direct secondary
was used at a concentration of 1:500 (Alexa 594). When
sections were double labelled with GFAP and NG2 with
also used the nuclear marker 4’,6-diamidino-2-phenylin-
dole (DAPI) as third stain. DAPI (1:10000) was added to
the final PBS wash. All sections were coverslipped with
Fluoromount Aqueous Mounting Medium (Sigma,
Poole, UK) to protect the fluorescence from fading and
stored in dark boxes at 4°C. Controls for immunohisto-
chemistry included omitting the first or second primary
antibodies. Each immunohistochemical experiment was
repeated with an N of three animals minimum for each
treatment and each set of double stain.
Real time reverse transcriptase polymerase chain reaction
(RT-qPCR) assay
Tissue collection and RNA preparation
For tissue collection, animals were terminally anaesthe-
tized with CO2 at 7 days after CFA injections, SNI or
sham surgery. The spinal cord segment corresponding
to the lumbar area was rapidly removed and the ipsilat-
eral and contralateral dorsal horn quadrant L4-L6 dis-
sected out and frozen on dry ice. Samples were then
stored at -80°C until further processing. Total RNA was
extracted from homogenized dorsal quadrant using an
acid phenol extraction method (TRIzol reagent, RNeasy
mini-columns, Qiagen, Crawley, UK). RNA concentra-
tion was calculated from the A260 value given by the
Nanodrop (Labtech International, UK). All samples
showing satisfactory quality were used for RT-qPCR.
RT-qPCR
RNA samples were treated with DNase I (Qiagen, Craw-
ley, UK). Equal amounts (1 μg) of total RNA were
reversed transcribed using random nonamers (Sigma,
Poole, UK), oligo(dT)15 primers (Promega, WI, US) and
Superscript TM III RT (Invitrogen, Carlsband, CA, US),
one hour at 50°C in a total reaction volume of 20 μl.
cDNAs were immediately quantified by real-time PCR
or kept at -20°C until further experiments. Real-time
PCR reactions were performed with DNA Engine (Bio-
Rad, CA) using QuantiTect SYBR Green RT-PCR Mas-
ter Mix (Qiagen, Crawley, UK) with each gene-specific
primers (see Table 1 for primers sequences). One μlo f
cDNA diluted 1/10 in H20 was amplified in a three-step
cycling program in a final reaction volume of 25 μl.
Control cDNA samples (obtained without transcriptase)
were always included, as well as samples without any
cDNA template. Efficiencies of PCR were calculated for
each gene using serial dilution. Reactions were per-
formed in triplicate minimum, and threshold cycle
values were normalized to b-Actin (CFA experiment) or
hypoxanthine guanine phosphoribosyl transferase
(HGPRT; SNI experiment) gene expression. The specifi-
city of the products was determined by melting curve
analysis. The ratio of the relative expression of target
genes to b-Actin or HGPRT was calculated by using the
2ΔCT formula. Then for each gene, the expression of
the ipsi and contralateral side was expressed as a per-
centage of the expression in sham animals (i.e. the mean
expression of sham animals was arbitrarily given the
value of 100% and the expression level for each single
sample was re-calculated accordingly).
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All images of double stained tissue were acquired by
confocal microscopy using a laser scanning microscope
(Leica TCS NT SP) as described before [47]. Post-acqui-
sition processing was performed with Adobe Photoshop
and Adobe Illustrator.
Quantitative analysis of MeCP2 expression in DRG
sections
We used confocal microscopy to measure MeCP2
expression within ATF3 positive and negative DRG neu-
rons. Gain and laser strength were set at the beginning
of this experiment and fixed throughout data collection.
Representative areas of the cell population in the DRG
sections were selected and scanned. Both cell bodies
and their corresponding nuclei were analysed to mea-
sure MeCP2 staining intensity. The intensity of staining
for each cell and nucleus was recorded in arbitrary
units. The area of each cell body and nucleus was
noted, as was the ATF3 staining status of the cell (posi-
tive or negative). Data from ipsilateral DRG sections
were processed individually for each animal. A value for
the relative total MeCP2 content for each neuronal
nucleus was calculated by multiplying the mean inten-
sity of MeCP2 immunofluorescence within each nucleus
by the area of the nucleus. Each nerve cell measured
was classified as either a small fibre (< 25 μm cell body
diameter) or large fibre (> 25 μm) neuron and further
sub-divided into groups depending on whether each cell
stained ATF3 positive or negative. For each group
(small and large fibres), the expression of ATF3 positive
fibres was expressed as a percentage of ATF3 negative
fibres (i.e. the mean expression of ATF3 negative fibre
was given the value of 100% and the expression level for
each nucleus re-calculated accordingly).
Statistical data analysis
All statistical tests were performed in IBM SPSS statis-
tics 20. To analyse qPCR data, we ran first a multivari-
ate analysis for each pain model (all genes validated
using the same samples were analysed at once) to con-
firm a treatment effect. The analysis was followed by an
univariate test to analyse each specific gene, with LSD
post-hoc analysis. To analyse MeCP2 expression in
ATF3 positive neurones data we used Student’s T-tests.
Data were always analysed as presented in the figures.
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